Erisyon

Erisyon is a private, pre-revenue biotech company commercializing a transformative single-molecule protein sequencing technology called Fluorosequencing. The platform, invented at the University of Texas at Austin, offers ultimate sensitivity, massively parallel throughput, and absolute quantification, positioning it to address critical gaps in proteomics left by mass spectrometry and RNA sequencing. Erisyon is initially targeting applications in oncology, neurology, and infectious disease, with the goal of fundamentally changing how diseases are detected, treated, and monitored.

Fluorosequencing: a single-molecule protein sequencing platform that uses fluorescent labeling, cyclic imaging, and Edman degradation to identify proteins with ultra-high sensitivity, massively parallel throughput, and absolute quantification.

Erisyon's primary competitors are established proteomics technologies: Mass Spectrometry (low sensitivity, sequential processing), RNA Sequencing (indirect, poor correlation), and Affinity Assays (qualitative, biased). Fluorosequencing aims to disrupt this landscape by offering a direct, digital, and highly parallel protein readout. It may also face future competition from other emerging protein sequencing technologies.